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Abstract Peptide nucleic acids (PNAs) are DNA analogs that
can hybridize to complementary sequences with high affinity and
stability. Here, we report the first evidence of intracellular
delivery of PNAs in vivo. Two CNS receptors, an opioid (mu)
and a neurotensin (NTR-1), were targeted independently by
repeated microinjection of PNAs into the periaqueductal gray.
Behavioral responses to neurotensin (antinociception and hy-
pothermia) and morphine (antinociception) were lost in a specific
manner. Binding studies confirmed a large reduction in receptor
sites. The loss of behavioral responses was long lasting but did
fully recover. The implications of specifically and readily turning
off gene expression in vivo are profound.
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1. Introduction
Peptide nucleic acids (PNAs) are a relatively new class of
molecules that have a neutral polyamide backbone with nu-
cleobases that allow complementary hybridization to DNA or
RNA. PNAs are stable against nucleases and proteases, bind
independently of salt concentration, and, due to their neutral
backbone, have a stronger a⁄nity for nucleic acids than do
DNA/DNA duplexes [1]. Additionally, PNA/DNA duplexes
are less tolerant of mismatches than DNA/DNA duplexes,
as a single mismatch in a 15-mer PNA/DNA duplex lowers
the Tm on average by 15‡C, thus making PNAs much more
gene speci¢c than oligomers [2].
In vitro antisense studies targeting a variety of mRNA and
DNA sequences have suggested that PNAs are potent inhib-
itors of protein production. This mechanism, while not com-
pletely understood, seems to be dependent on the base content
of the PNA: mixed purine/pyrimidine sequences inhibit trans-
lation by forming duplexes with mRNA, while homopyrimi-
dines inhibit transcription elongation by forming triplexes
with ds DNA [3,4].
With these superior properties of PNAs, initial enthusiasm
for their use as antisense or antigene drugs was dampened by
the observations that these molecules passed poorly into cells
[5,6]. This poor permeability is likely due to their low phos-
pholipid membrane permeability [7]. Although researchers
have made derivative forms of PNAs to enhance transport
into cells [8,9], there is no information whether these altered
PNAs are able to inhibit protein expression.
Despite these reports, we chose to use unmodi¢ed PNAs to
examine the role of neurotensin receptors in behavioral and
physiological responses to neurotensin (NT) in vivo. NT is an
endogenous tridecapeptide that is found throughout the mam-
malian central nervous system. Many studies show that NT is
a neurotransmitter or neuromodulator capable of exerting
potent e¡ects, including hypothermia and antinociception
[10,11]. NT receptors (NTRs) are also distributed heterogene-
ously in the central nervous system with both high and low
a⁄nity (levocabastine-sensitive) sites [12]. NTR-1 (high a⁄n-
ity) has been molecularly cloned from both human and rat
cDNA [13^15]. NTR-2 and its species homolog, NTRL, were
identi¢ed in rat hypothalamic and mouse brain cDNA library,
respectively [16,17].
Many groups, including ours, have long hypothesized that
the hypothermic and antinociceptive e¡ects of NT are medi-
ated by yet uncharacterized receptor subtypes. This hypothesis
is supported by the observation that SR48692, a non-peptide
NT antagonist, fails to antagonize the antinociceptive and
hypothermic e¡ects of NT [18,19]. SR48692 is much less po-
tent at binding to NTR-2 (IC50 = 300 nM) compared to that at
NTR-1 (IC50 = 5.6 nM) [20]. Additionally, D-Trp11-NT, a po-
tent hypothermic and antinociceptive analog has a relatively
high a⁄nity at the NTR-2 (IC50 = 25 nM), compared to that
at the rat NTR-1 (IC50 = 320 nM) [21]. Lastly, we have dem-
onstrated that the levocabastine-sensitive NTR-2, is not likely
responsible for the hypothermic and antinociceptive responses
of NT [22].
We, therefore, reasoned that if the mechanisms of NT-
mediated hypothermia and antinociception were controlled
through di¡erent NT receptor subtypes, inhibiting production
of NTR-1 should have no e¡ect on these NT-mediated re-
sponses. However, this would leave us with a negative result,
which would be di⁄cult to prove and could be ascribed to
lack of transport of the PNA delivery into cells. In addition,
no one has shown that PNAs can a¡ect any cellular function.
Thus, for a positive control, we also designed and developed
PNAs to inhibit production of the mu receptor upon which
morphine speci¢cally acts to produce antinociception.
2. Materials and methods
2.1. PNA synthesis
PNAs were synthesized with Fmoc-N-(2-aminoethyl) glycyl PNA
monomers on an Expidite 8909 Nucleic Acid Synthesizer according
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to the chemistry and protocols developed by the manufacturer (Per-
septive Biosystems, Inc., Framingham, MA). The exocyclic amines of
the bases adenine, guanine, thymine and cytosine of each Fmoc-PNA
monomer were protected with the blocking group benzhydryloxycar-
bonyl (Bhoc). Synthesis of the PNAs (2U2 Wmole) was on PAL-Poly-
ethylene Glycol-Polystyrene resin (Perseptive Biosystems) which pro-
duces a carboxamide group (CONH2) at the COOH terminus (3P)
end. After synthesis, the PNAs were deprotected and removed from
the polystyrene-resin by treatment with a mixture of 80% tri£uoracetic
acid (TFA) containing 20% m-Cresol for 90 min at 22‡C. PNAs were
then precipitated in diethyl ether, and puri¢ed by RP-HPLC on a
Vydac C18 column at 60‡C with a bu¡er of 0.1% aqueous TFA and
a linear gradient of 0.1% TFA containing 80% acetonitrile/20% water.
A major peak (at A300nm) was collected, lyophilized, and veri¢ed for
its correct mass weight by ESI mass spectrometry on a Sciex 165 MS
System (Perkin-Elmer, Foster City, CA).
2.2. Animal testing
Male Sprague-Dawley rats (Harlan, Prattville, AL; 180^200 g) were
stereotaxically implanted with stainless steel guide cannulae (26 gauge)
into the PAG under sodium pentobarbital anesthesia (50 mg/kg, i.p.)
as described [23]. The PAG cannulations were performed using the
following coordinates 35.6 (posterior) from bregma, lateral 1.0, 5.5
mm down from the dura. The ¢rst microinjection did not start until
5^7 days after surgery. Animals were maintained on a normal light/
dark cycle and testing occurred during the light cycle.
Using separate animals for each type of PNA, we microinjected the
+103 and RMOR in parallel into rats surgically cannulated in the
periaqueductal gray (PAG) region of the brain [11]. The PAG was
chosen because it is the region of the brain primarily involved in
processing nociceptive information and has a high density of NTR-
1 and mu receptors [24,25]. Injections of 1.3 nmol in arti¢cial cere-
brospinal £uid (ACSF) were given on days 34, 32, 0 and testing with
either NT (Mayo Protein Core Facility, Rochester, MN) or morphine
(Research Biochemicals Inc., Natick, MA) began on day 1 and con-
tinued until the response returned to baseline.
Animals being tested with NT (18 nmol) microinjected into the
PAG, had baseline hot plate and body temperatures determined im-
mediately prior to the experiment, while those tested for morphine (5
mg/kg i.p.) response had baseline tail £ick scores recorded. Thirty
minutes after microinjection of NT, the rat was placed on the hot
plate and latency was measured as described [11]. Immediately after
the 30 min hot plate trial, body temperature was measured using a
thermistor probe inserted 3 cm into the rectum. Animals receiving
morphine were tested using the tail £ick assay as described [26] except
the distal 3 cm of a restrained rat’s tail was placed in mineral oil at
60‡C and elapsed time was measured until the animal £icked its tail.
Hot plate and tail £ick assays were scored as the percent of maximum
possible e¡ect (% MPE) and calculated using the following equation:
% MPE = [(post-drug latency3pre-drug latency)/(cut-o¡3pre-drug la-
tency)]U100; where the cut-o¡ was 30 s for hot plate and 12 s for tail
£ick. Cannulated animals were decapitated and the brains removed
for veri¢cation of the cannula placement by comparison to stereotaxic
plates [27]. Only data from animals with a correct cannula placement
were included in the study.
2.3. Binding experiments
For NT competition binding assay, homogenates were prepared
from freshly obtained PAG and hypothalamus of adult rats as pre-
viously described [28]. Competition binding assays were carried out as
previously described [29] with the following modi¢cations: binding
bu¡er also contained 0.5% glycerol, 0.01 mM phenylmethylsulfonyl-
£uoride, 7 WM pepstatin, 0.8 WM aprotonin, 12 WM leupeptin, 0.1 mM
iodoacetamide and 0.25 mM EDTA (all from Fisher Scienti¢c, Pitts-
burgh, PA), but did not contain N-benzyloxycarbonyl prolyl prolinal.
Brain homogenate (1 mg wet wt. of protein) was incubated with
[125I]NT (0.2 nM) (NEN, Boston, MA) and increasing concentrations
of unlabeled NT in total volume of 100 Wl. For the morphine com-
petition binding assay, homogenates and competition binding assays
were prepared from freshly obtained PAG of adult rats as previously
described [30] with the following modi¢cations: assays were per-
formed in 1 ml 96 well plates, 2.5 mg wet wt. protein per well and
2 nM [3H]morphine (NEN, Boston, MA).
3. Results
We chose to target the mu and the NTR-1 at the genomic
level as well as at the mRNA level by designing PNAs that
could bind to either mRNA or the parallel DNA sequence.
The PNA to the mu receptor (RMOR) was pyrimidine rich to
aid in ds DNA strand invasion, while the PNA to the NTR-1
(+103) had mixed types of bases. Previous antisense work on
the mu receptor elucidated an e¡ective exon target, so we
designed our PNA to bind to this region [26]. The NTR-1
gene has been molecularly cloned and we targeted our PNA
to an area starting +103 bp from the start codon (within the
coding region), an area predicted to have high secondary
structure. The scrambled control (SCR) had the same number
and type of bases as the RMOR, only randomly ordered
(Table 1).
Rats given +103 and tested with NT had antinociceptive
responses at approximately 10% MPE (P6 0.001 vs. NT
alone; Fig. 1A) and body temperature change of approxi-
mately 30.4‡C (P6 0.001 vs. NT alone; Fig. 1B). RMOR
treated rats tested with morphine scored approximately 30%
MPE (P6 0.001 vs. morphine alone; Fig. 1A). The +103 ani-
mals recovered more quickly than the animals treated with
RMOR, with a signi¢cant return of MPE by day 5
(Ps 0.06 vs. baseline; Fig. 2) and a signi¢cant BT return by
day 6 (Ps 0.1 vs. baseline; Fig. 2), both responses were re-
covered fully by day 11 (Ps 0.9 vs. baseline; Fig. 2). The
RMOR treated animals took until day 14 to fully recover
MPE (Ps 0.9 vs. baseline; Fig. 2). Thus, for both PNA
treated groups, the corresponding response to the drug was
signi¢cantly decreased but all responses did recover to the
baseline level of untreated animals.
In order to determine that these losses were speci¢c to the
proteins targeted, animals treated with +103 were tested with
morphine, and animals treated with RMOR were tested with
NT. There was no signi¢cant di¡erence between the antinoci-
ceptive or body temperature responses of these groups and
animals that received no PNAs (Ps 0.5; Fig. 1A, B). Addi-
tionally, to ensure that there was no nonspeci¢c PNA inter-
action in the cells, SCR was given to another set of animals in
the exact manner described. These animals showed no signi¢-
cant change in their antinociceptive response to morphine
compared to controls (Ps 0.3). Vehicle control, ACSF, ani-
mals also had no change in their body temperature and anti-
nociceptive response to NT or morphine compared to un-
treated control animals (Ps 0.9).
The speci¢c loss of responses to morphine and NT were
likely due to the reduced synthesis of the respective receptors
caused by their antisense PNAs. To test this hypothesis, we
treated animals with either +103 or RMOR injected into the
PAG and tested for binding and receptor number at day 1
(lost response) and compared these data to normal controls
(Table 2). The KDs for NT in the PAG and hypothalamus and
morphine in the PAG were unchanged between untreated
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Table 1
PNA sequences and names
Target gene PNA name PNA sequence
NTR-1 +103 5P-CATTGCTCAAAC-3P
mu RMOR 5P-CAGCCTCTTCCTCT-3P
none SCR (scrambled) 5P-TCCTCCTCCACTTG-3P
B.M. Tyler et al./FEBS Letters 421 (1998) 280^284 281
control, vehicle (ACSF), scrambled (SCR) and treated ani-
mals who lost their behavioral response (either +103 or
RMOR). However, in +103 treated animals who had lost their
antinociceptive and hypothermic responses to NT, the number
of NT receptor binding sites decreased 39% and 46% in the
PAG and hypothalamus, respectively. Importantly, this
change in the number of NT receptor binding sites in the
hypothalamus indicates the ability of PNAs to di¡use or mi-
grate readily through CNS tissue. Signi¢cantly, there was no
change in the number of NT receptors in RMOR or SCR
treated animals, indicating the speci¢city of the PNA for the
targeted protein. Furthermore, RMOR treated animals
showed a large decrease, 53%, in the number of morphine
binding sites as compared to control animals. Again, there
was no signi¢cant di¡erence between the number of morphine
binding sites for the SCR treated, ACSF and control animals
indicating the e¡ects of the speci¢c PNAs were, indeed, spe-
ci¢c.
4. Discussion
Our results were truly novel and surprising for two major
reasons: (1) naked PNAs cross cell membranes in vivo and
speci¢cally inhibit protein expression and (2) our original hy-
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Fig. 1. A: % MPE for untreated, ACSF, +103, or RMOR PNA treated animals. PNA treated animals received 1.3 nmol of either +103 or
RMOR microinjected into the PAG on days 34, 32, and 0, and testing was on day 1. Animals were tested for their hot plate antinociceptive
response to either NT microinjected into the PAG (18 nmol) or their tail £ick antinociceptive response to morphine (5 mg/kg i.p.). Data are re-
ported as % MPE þ S.E.M. as calculated 30 min after drug delivery. The treatment before the ‘/’ indicates pretreatment into the PAG on days
34, 32, 0 while the drug listed after the ‘/’ indicates the drug used for testing. *P6 0.001 vs. NT alone, **Ps 0.98 vs. NT alone, open dagger
Ps 0.5 vs. morphine alone, 2P6 0.001 vs. morphine alone, ***Ps 0.9 vs. NT alone, VPs 0.99 vs. morphine alone, OPs 0.3 vs. morphine
alone. B: Body temperature change for untreated, ACSF, +103, or RMOR PNA treated animals. Body temperature was measured using a
thermistor probe inserted 3 cm into the rectum prior to and 30 min after NT (18 nmol) microinjection into the PAG. The change in body tem-
perature þ S.E.M. is reported. The treatment before the ‘/’ indicates pretreatment into the PAG on days 34, 32, 0 while the drug listed after
the ‘/’ indicates the drug used for testing. *P6 0.001 vs. NT alone, **Ps 0.9 vs. NT alone, ***Ps 0.3 vs. NT alone.
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pothesis that a PNA directed to the NTR-1 would have no
e¡ect on NT-mediated behavioral responses was not correct.
Recently [31], it was reported that PNAs could cross cell
membranes of immortalized and transformed cell lines, but
the functional e¡ect of the PNAs was not examined. Others
[32] have reported that Technetium-99m-labeled PNAs are
able to hybridize in vivo to beads conjugated with the com-
plementary strand, indicating the stability of PNAs in vivo.
Another group [9] has examined the transport of 125I-biotiny-
lated PNA with and without a vector, following intravenous
administration and reported that the vector-conjugated PNA
was able to cross the blood-brain barrier, further indicating
their stability within the CNS. However, none of these groups
examined the ability of naked PNAs to cross cell membranes
in vivo or their e¡ects on protein production. In some cases
the PNAs examined were signi¢cantly modi¢ed and the deliv-
ery was systemic. Thus, the key to PNAs crossing cell mem-
branes in vivo may lie in the fact that when left unmodi¢ed,
these small neutral molecules are able to cross the cell mem-
brane functionally intact. The addition of other molecules to
the PNA in order to add a tag, such as a radiolabel, may
allow for visualization of the PNA, but may also hinder the
transport of the PNA into the cell.
While our initial hypothesis regarding NT-mediated re-
sponses may not be correct, we think it is still possible that
another NT receptor subtype is responsible for its hypother-
mic and antinociceptive e¡ects. In fact, all the evidence to
date still strongly suggests that there are other NT receptor
subtypes responsible for these NT-mediated e¡ects. The anti-
sense PNA directed to the NTR-1 was targeted to a coding
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Fig. 2. Time course of hypothermia and antinociceptive responses in +103 or RMOR PNA treated rats. PNA treated animals received 1.3
nmol of either +103 or RMOR microinjected into the PAG on days 34, 32, and 0 and testing began on day 1 and continued until there was
no di¡erence compared to untreated animals. Untreated control animals tested with either NT or morphine were used to calculate the baseline
responses which were set to 100. Data are reported as a percentage of the baseline response þ S.E.M. as calculated 30 min after drug delivery.
+103 treated animals were tested with NT microinjected into the PAG (18 nmol) and were monitored for body temperature (a, n = 23) and hot
plate MPE scores (b, n = 23). RMOR treated animals were tested with morphine (5 mg/kg i.p.) for antinociception using the tail £ick assay
(R, n = 10).
Table 2
Comparison of binding results with NT and morphine in neuronal homogenates from rats treated in vivo with PNAs
Pretreatment Status of response to NT NT Bmax NT Bmax Morphine RMOR Bmax RMOR Bmax
NT Morphine KD
(nM)
fmol/mg
wet wt.
% change
vs. control
KD
(nM)
fmol/mg
wet wt.
% change
vs. control
PAG
none control normal normal 10 þ 1 13.5 þ 0.9 ^ 2.2 þ 0.2 1.7 þ 0.1 ^
ACSF normal normal 12 þ 1 14 þ 2 7.4 2.2 þ 0.5 1.6 þ 0.1 35.9
SCR normal normal 12 þ 1 13 þ 1 30.7 2.1 þ 0.1 1.5 þ 0.1 312
+103 lost normal 10 þ 1 8.2 þ 0.8* 339* N.D. N.D. N.D.
RMOR normal lost 12 þ 1 13.4 þ 0.2 30.7 1.6 þ 0.2 0.8 þ 0.1* 353*
Hypothalamus
none control normal normal 12 þ 1 16.4 þ 0.9 ^
ACSF normal normal 13 þ 1 18 þ 2 7.9
SCR normal normal 14 þ 1 17 þ 1 1.2
+103 lost normal 11 þ 1 8.9 þ 0.8* 346*
RMOR normal lost 13 þ 1 15.7 þ 0.2 34.3
*P6 0.05 vs. none control.
N.D., not determined.
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region of this gene and is only a 12-mer. This short coding
region may be conserved between the NT receptor subtypes
and thus may be inhibiting the synthesis of more than one
subtype of NTR.
The long lasting e¡ects of the PNAs, the complete return of
the responses, and a comparison of kinetics between the mu
receptor and NTR-1 are intriguing. Obviously, further experi-
ments must be done in order to gain a fuller understanding of
how PNAs are blocking protein expression and what happens
to the PNAs within the animal and within the cell. The two
PNAs examined here were directed against cell surface recep-
tors and the applicability to other types of proteins has yet to
be examined. However, it is clear, despite evidence in the
literature to the contrary, that PNAs do present a new and
potentially powerful method of speci¢cally a¡ecting protein
regulation in vivo.
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